Pharming Group Overview
- Founded
-
1988

- Status
-
Public
- Employees
-
332

- Stock Symbol
-
PHARM

- Investments
-
8
- Share Price
-
$1.23
- (As of Tuesday Closing)
Pharming Group General Information
Description
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.
Contact Information
- Darwinweg 24
- 2333 CR Leiden
- Netherlands
Pharming Group Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.23 | $1.27 | $0.69 - $1.54 | $809M | 656M | 11.5M |
Pharming Group Financials Summary
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
---|---|---|---|---|
EV | 830,841 | 704,305 | 548,434 | 969,182 |
Revenue | 201,546 | 205,622 | 198,871 | 212,174 |
EBITDA | 17,178 | 30,232 | 39,354 | 57,637 |
Net Income | (1,995) | 13,674 | 15,996 | 37,746 |
Total Assets | 422,996 | 425,797 | 397,315 | 418,453 |
Total Debt | 170,399 | 166,694 | 161,761 | 161,959 |
Pharming Group Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Pharming Group Comparisons
Industry
Financing
Details
Pharming Group Competitors (29)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
000000 | Formerly PE-Backed | Hamburg, Germany | 0000 | 00000 | 000000000 | 00000 |
0000000000 0000000 | Corporation | Ingelheim am Rhein, Germany | 00000 | |||
000000 | Formerly PE-Backed | Bengaluru, India | 00000 | 000.00 | 00000000 | 000.00 |
000000 00000000000 | Formerly PE-Backed | South San Francisco, CA | 00 | 00000 | 000000&0 | 00000 |
Pharming Group Patents
Pharming Group Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3175603-A1 | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress | Pending | 17-Apr-2020 | 000000000 | |
EP-3895726-A1 | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress | Inactive | 17-Apr-2020 | 000000000 | 00 |
EP-4135756-A1 | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress | Pending | 17-Apr-2020 | 000000000 | |
US-20210324107-A1 | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress | Pending | 17-Apr-2020 | 000000000 | |
AU-2019226355-A1 | Treatment and prevention of pre-eclampsia | Pending | 28-Feb-2018 | A61K38/57 |
Pharming Group Executive Team (16)
Pharming Group Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
A. De Winter | Pharming Group | Chairman of the Audit Committee and member of the Corporate Governance Committee | 000 0000 |
Barbara Yanni JD | Self | Board Member | 000 0000 |
Deborah Jorn | Pharming Group | Vice-Chairwoman of the Board of Directors, Member of the Audit Committee and Chairwoman of the Remuneration Committee | 000 0000 |
Leonard Kruimer | Self | Board Member | 000 0000 |
Mark Pykett Ph.D | Self | Board Member | 000 0000 |
Pharming Group Signals
Pharming Group Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Pharming Group Investments & Acquisitions (8)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 0000 | 01-Jan-2020 | 000000000 | Buildings and Property | ||
00000000 (000 | 13-Aug-2019 | 000000000 | 0000 | Buildings and Property | |
0000000000000 | 09-Apr-2019 | 000000000 | 00.000 | BPO/Outsource Services | 000000 00 |
0000000000000 | 09-Apr-2019 | 000000000 | BPO/Outsource Services | 000000 00 | |
Ruconest (North American commercialization rights) | 08-Dec-2016 | Corporate Asset Purchase | 00000 | Buildings and Property |
Pharming Group ESG
Risk Overview
Risk Rating
Updated November, 08, 2022
27.93 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,233
Rank
Percentile

Pharmaceuticals
Industry
00 of 866
Rank
Percentile

Biotechnology
Subindustry
00 of 382
Rank
Percentile

Pharming Group Exits (1)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
00000 | 23-Mar-2006 | 000000000000000000 | Completed |
|